BENTONVILLE, Arkansas and
NEW YORK, Dec. 3, 2019 /PRNewswire/ -- Global digital
therapeutics innovation leader, DarioHealth Corp. (NASDAQ: DRIO)
announced today the launch of the Dario-powered digital diabetes
program on Walmart.com.
Walmart is the largest retailer in the world and is the second
largest e-commerce retailer in the U.S. It is also an innovator in
healthcare, piloting several initiatives such as opening its own
Walmart Health centers and creating a Home Health Care section on
Walmart.com.
The Dario digital diabetes app is among the most downloaded and
highest rated healthcare apps, with a 4.9/5.0 star rating and over
8,000+ reviews on the Apple store. Its Net Promoter Score (NPS), a
measure of willingness of customers to recommend a company's
products or services to others, is +77, considered "world class"
and the highest in its category, on a -100 - +100
scale.
"Walmart strives to offer its shoppers health solutions that
will help them manage their own health in the most efficient way
possible. We are excited to access Walmart's online distribution
channel given the extremely high volume of annual visitors. We will
offer Walmart's consumers MyDario™, our complete
digital solution to manage diabetes, hypertension, nutrition and
exercise. Our system is affordable and supported by a large body of
clinical evidence that we believe demonstrates that Dario
significantly and quickly improves the health and wellness of its
users. We believe that the positive results seen while using our
system reinforces engagement and are part of the reason why users
rate Dario as one of the best solutions for managing chronic
conditions," said Olivier Jarry,
DarioHealth's President and Chief Commercial Officer.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital
health company serving its users with dynamic mobile health
solutions. In today's day and age, knowledge of health and
treatment is being democratized, and we believe people deserve to
know everything about their own health and have the best tools to
manage their condition. DarioHealth employs a revolutionary
approach whereby harnessing big data, we have developed a novel
method for chronic disease data management, empowering people to
analyze and personalize self-diabetes management in a totally new
way without having the disease slow them down. DarioHealth has a
commercial office in New York with
an R&D center in Caesarea,
Israel.
For more information, visit
http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company
discusses its belief that the existing body of evidence with
respect to its system demonstrates that Dario significantly and
quickly improves the health and wellness of its users and the
belief that the positive results seen while using its system
reinforces engagement and are part of the reason why users rate
Dario as one of the best solutions for managing chronic
conditions, it is using forward-looking statements. Readers
are cautioned that certain important factors may affect the
Company's actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and
prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade,
legal, social and economic risks, and the risks associated with the
adequacy of existing cash resources. Additional factors that could
cause or contribute to differences between the Company's actual
results and forward-looking statements include, but are not limited
to, those risks discussed in the Company's filings with the U.S.
Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and
results of the Company's commercial and regulatory plans for
Dario™) may differ significantly from those set forth
in the forward-looking statements. The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
DarioHealth Corporate Contact:
Claudia
Levi
Content & Communications Manager
claudia@mydario.com
Tel: +1-347-767-4220
View original content to download
multimedia:http://www.prnewswire.com/news-releases/walmart-starts-distributing-the-dariohealth-digital-diabetes-management-system-300968169.html
SOURCE DarioHealth Corp.